WORLD PEPTIDEFOUNDATION

Where is Desmopressin being studied?

Find registered human studies, phases, products, recruitment status and reported research locations around the world. Registry search matches are separate from this profile’s reviewed evidence.

Find studies for Desmopressin →Worldwide registry directory

Scientific intelligence record

Experience 2.0

Vasopressin analog

Desmopressin

Desmopressin is a synthetic analog of arginine vasopressin modified by deamination at position 1 and D-arginine at position 8. It preferentially activates renal V2 receptors, increasing collecting-duct water reabsorption through aquaporin-2 trafficking; V2-mediated endothelial release of von Willebrand factor and factor VIII underlies selected haemostatic uses. Clinical effects and risks differ materially by indication, dose, route, formulation, renal function, fluid intake, age, and concomitant medicines.

Record status

Traceability partial

Last meaningful update: 9/20/2026

Evidence searched through:
Not recorded
Assessment updated:
9/20/2026
Documented human review:
No documented human review recorded
Automated scientific assessment:
9/26/2026
AI source check:
9/26/2026

Published source links and profile text pass separate gates. Only a documented human review is labelled as human review; an automated scientific assessment applies deterministic checks, and an AI source check confirms only that a source exists and matches its identifiers. A source count alone does not establish a review.

Evidence coverage has three distinct layers. The corpus count is a transparent screening inventory, the featured set contains study-level tiering and interpretation, and the published-source count contains records promoted through the institutional publication workflow. Source validation, editorial publication, and scientific appraisal are separate decisions; these numbers must not be merged.

Ranked research corpus

500

Categorized publications with provisional ranking; scientific review remains separate.

Featured tiered studies

0

Cornerstone publications with study-level interpretation, limitations, and tier disclosure.

Research domains

6

Clinical and scientific questions synthesized independently across the evidence atlas.

Published source records

26

Database records promoted through the governed publication workflow—not the corpus total.

Corpus generated 2026-09-18. Counts remain separately labeled so screening is not represented as completed review.

Human experience · separate evidence stream

No community pattern is displayed yet

Eligible observations remain below the privacy and reliability threshold. WPF will not convert a handful of reports into a percentage, trend, or clinical claim.

Observation is valuable human context. It is not evidence of causation, efficacy, or safety.

Public display gate

n ≥ 20 eligible observations

Exact progress remains private before the threshold.

Contribute an observationArchive details

Intelligence snapshot

The state of the record

A compact view of what is represented, what remains unresolved, and how completely the record can be traced.

Ranked research corpus

500

Categorized screening records; proposed rankings remain pending human appraisal.

Featured tiered studies

0

Cornerstone studies with published study-level interpretation and tier disclosure.

Research domains

6

Independent evidence dossiers covering the major research questions.

Published source records

26

Source records published through the governed workflow; this count does not certify scientific conclusions.

Contradictions

0

Conflicting evidence relationships that remain visible.

Research gaps

1

Questions the current record identifies as unresolved.

Connected media

0

Media records explicitly linked to this scientific record.

What we know

Evidence, claims, and boundaries

The project separates represented evidence from qualification, contradiction, uncertainty, and what the evidence does not establish.

Reconciled domain conclusions

6 published domain syntheses connected to 0 featured studies

Desmopressin no longer relies on the legacy “no public claim” state. Each research domain publishes a bounded synthesis, confidence level, evidence context, limitations, geographic applicability, regulatory interpretation, and research gaps. Publication of these syntheses is separate from the scientific review status shown above.

Inspect the reconciled evidence atlas
Inspect the published evidence record26 governed records · titles, provenance, and original-source linksOpen records ↓
2020Phase 3 human evidence
Evidence strength A · 91/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Efficacy and safety of 25 and 50 μg desmopressin orally disintegrating tablets in Japanese patients with nocturia due to nocturnal polyuria: Results from two phase 3 studies of a multicenter randomized double-blind placebo-controlled parallel-group development program.

This study assessed the efficacy and safety of desmopressin orally disintegrating tablets (ODTs) in Japanese males (50 and 25 μg) and females (25 μg) with nocturia due to nocturnal polyuria (NP).

Authors
Osamu Yamaguchi, Kristian V Juul, Ali Falahati, Toru Yoshimura, Futoshi Imura, Mikiya Kitamura
Source
Lower urinary tract symptoms
DOI
10.1111/luts.12276
PubMed
31397969
Open original source
2002Phase 3 human evidence
Evidence strength A · 91/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men.

To investigate the efficacy and safety of oral desmopressin in the treatment of nocturia in men.

Authors
A Mattiasson, P Abrams, P Van Kerrebroeck, S Walter, J Weiss
Source
BJU international
DOI
10.1046/j.1464-410x.2002.02791.x
PubMed
12010228
Open original source
2023Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Desmopressin for patients with spontaneous intracerebral haemorrhage taking antiplatelet drugs (DASH): a UK-based, phase 2, randomised, placebo-controlled, multicentre feasibility trial.

The risk of death from spontaneous intracerebral haemorrhage is increased for people taking antiplatelet drugs.

Authors
Michael J R Desborough, Rustam Al-Shahi Salman, Simon J Stanworth, Diane Havard, Lisa J Woodhouse, Jennifer Craig, Kailash Krishnan, Paul M Brennan, Robert A Dineen, Tim J Coats, Trish Hepburn, Philip M Bath
Source
The Lancet. Neurology
DOI
10.1016/s1474-4422(23)00157-6
PubMed
37353276
Open original source
1995Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Response to desmopressin as a function of urine osmolality in the treatment of monosymptomatic nocturnal enuresis: a double-blind prospective study.

To determine if urine osmolality parameters can predict whether children with primary monosymptomatic nocturnal enuresis will respond to desmopressin, we conducted a prospective, double-blind, placebo-controlled study in 96 children 8 to 14 years old.

Authors
H G Rushton, A B Belman, M Zaontz, S J Skoog, S Sihelnik
Source
The Journal of urology
DOI
10.1097/00005392-199508000-00112
PubMed
7609170
Open original source
2011Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Randomized comparison of long-term desmopressin and alarm treatment for bedwetting.

To compare the efficacy of long-term primary nocturnal enuresis (PNE) treatment using desmopressin versus enuresis alarm.

Authors
Jonathan Evans, Birgitta Malmsten, Alison Maddocks, Harbans Singh Popli, Henri Lottmann, UK study group
Source
Journal of pediatric urology
DOI
10.1016/j.jpurol.2010.04.018
PubMed
20579938
Open original source
2004Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Evidence against a synergistic effect of desmopressin with conditioning in the treatment of nocturnal enuresis.

To test the hypothesis that desmopressin facilitates acquisition of continence, we aimed to establish whether, in children with nocturnal enuresis who are desmopressin nonresponders, adjunct desmopressin increases the rate of sustained continence after treatment with a conditioning alarm.

Authors
Susie Gibb, Terry Nolan, Mike South, Lea Noad, Giles Bates, Suzanna Vidmar
Source
The Journal of pediatrics
DOI
10.1016/j.jpeds.2003.12.019
PubMed
15001941
Open original source
2001Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Desmopressin usage in elective cardiac surgery.

Desmopressin acetate (DDAVP) has been implicated as a promising agent to reduce blood loss in patients undergoing cardiopulmonary bypass.

Authors
E Ozkisacik, F Islamoğlu, H Posacioğlu, T Yağdi, S Başarir, S B Omay, M Ozbaran, S Büket
Source
The Journal of cardiovascular surgery
PubMed
11698939
Open original source
1999Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Desmopressin resistant enuresis: pathogenetic and therapeutic considerations.

We tested the role of the bladder in the pathogenesis of desmopressin resistant enuresis by evaluating the influence of urine production on the timing of the enuretic event and the response to anticholinergic medication.

Authors
T Nevéus, G Läckgren, T Tuvemo, U Olsson, A Stenberg
Source
The Journal of urology
DOI
10.1016/s0022-5347(05)68142-6
PubMed
10569604
Open original source
1999Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Desmopressin in the treatment of nocturnal polyuria in the male.

To assess whether desmopressin (1-desamino 8-d-arginine vasopressin) is safe and effective in the treatment of nocturnal polyuria in elderly men.

Authors
A Cannon, P G Carter, A A McConnell, P Abrams
Source
BJU international
DOI
10.1046/j.1464-410x.1999.00125.x
PubMed
10444118
Open original source
1987Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

1-Desamino-8-D-arginine vasopressin (desmopressin) decreases operative blood loss in patients having Harrington rod spinal fusion surgery. A randomized, double-blinded, controlled trial.

To evaluate the effect of 1-desamino-8-D-arginine vasopressin (desmopressin) on blood loss in surgery, we conducted a randomized, double-blind trial of the drug in 35 patients with normal hemostatic function who were having spinal fusion with Harrington rod instrumentation.

Authors
N L Kobrinsky, R M Letts, L R Patel, E D Israels, R C Monson, N Schwetz, M S Cheang
Source
Annals of internal medicine
DOI
10.7326/0003-4819-107-4-446
PubMed
3631784
Open original source
2010Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Desmopressin improves platelet dysfunction measured by in vitro closure time in uremic patients.

Desmopressin decreases bleeding time in uremic patients.

Authors
Hyun Kee Lee, Yoon Ji Kim, Jin Uk Jeong, Jung Sik Park, Hyun Sook Chi, Soon Bae Kim
Source
Nephron. Clinical practice
DOI
10.1159/000276576
PubMed
20090366
Open original source
2022Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Moderate-intensity aerobic exercise vs desmopressin in adolescent males with mild hemophilia A: a randomized trial.

Persons with mild hemophilia A (HA) may use intranasal desmopressin prior to sports participation.

Authors
Riten Kumar, Amy L Dunn, Jane E Schneiderman, Anne Gonzales, Vanessa Bouskill, Pamela Widener, Joseph Stanek, Fred G Pluthero, Amanda Waller, Cristina Tarango, Sanjay Ahuja, Bryce A Kerlin
Source
Blood
DOI
10.1182/blood.2022016146
PubMed
35839450
Open original source
2018Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Claiming desmopressin therapeutic equivalence in children requires pediatric data: a population PKPD analysis.

For a new formulation of a drug, only pharmacokinetic bioequivalence with the original formulation has to be demonstrated in healthy, young adults.

Authors
Robin Michelet, Lien Dossche, Charlotte Van Herzeele, Jan Van Bocxlaer, An Vermeulen, Johan Vande Walle, SAFE-PEDRUG consortium
Source
European journal of clinical pharmacology
DOI
10.1007/s00228-017-2386-0
PubMed
29198064
Open original source
2016Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Desmopressin after cardiac surgery in bleeding patients. A multicenter randomized trial.

Previous studies showed that desmopressin decreases post-operative blood loss in patients undergoing cardiac surgery.

Authors
E Bignami, M Cattaneo, G Crescenzi, M Ranucci, F Guarracino, C Cariello, R Baldassarri, G Isgrò, E Baryshnikova, G Fano, A Franco, C Gerli
Source
Acta anaesthesiologica Scandinavica
DOI
10.1111/aas.12740
PubMed
27117753
Open original source
2016Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Side effects of desmopressin in patients with bleeding disorders.

Desmopressin is frequently used in patients with bleeding disorders because of its prohaemostatic effects.

Authors
S C M Stoof, M H Cnossen, M P M de Maat, F W G Leebeek, M J H A Kruip
Source
Haemophilia : the official journal of the World Federation of Hemophilia
DOI
10.1111/hae.12732
PubMed
26036844
Open original source
2025Observational human evidence
Evidence strength A · 88/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Desmopressin for nocturnal enuresis in children.

Enuresis (bedwetting) affects up to 20% of five-year-old children and 2% of adults.

Authors
Deirdre Hahn, Fiona Stewart, Gayathri Raman
Source
The Cochrane database of systematic reviews
DOI
10.1002/14651858.cd002112.pub2
PubMed
40728007
Open original source
2016Observational human evidence
Evidence strength A · 88/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Desmopressin effectiveness in renal colic pain management: Systematic review and meta-analysis.

This meta-analysis of trials was conducted to evaluate the impact of desmopressin on renal colic pain relief in comparison to more typically used medications (opioids and nonsteroidal anti-inflammatory drugs [NSAIDs]).

Authors
Mohammad Jalili, Pouya Entezari, Amin Doosti-Irani, Rasoul Masoomi, Hadi Mirfazaelian
Source
The American journal of emergency medicine
DOI
10.1016/j.ajem.2016.05.020
PubMed
27289437
Open original source
2019Observational human evidence
Evidence strength A · 88/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Efficacy and safety of desmopressin in women with nocturia: a systematic review and meta-analysis of randomized controlled trials.

To evaluate the efficacy and safety of desmopressin treatment in women with nocturia.

Authors
Xiang Cai, Yiyang Tian, Ming Nie, Kunjie Wang
Source
International urology and nephrology
DOI
10.1007/s11255-019-02242-x
PubMed
31352583
Open original source
2025Observational human evidence
Evidence strength A · 88/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Effect of desmopressin on bleeding outcomes after native renal biopsy: a systematic review and meta-analysis.

Percutaneous kidney biopsy is a key diagnostic tool in nephrology but carries a risk of post-procedure bleeding, with complications ranging from minor hematomas to life-threatening hemorrhages.

Authors
Ammar Yasser Ali, Rem Ehab Abdelkader, Rashad G Mohamed, Mohammed N Abdelaziz, Radwa M Abdelsattar, Ahmed R A Moustafa, Mohamed Rizk Elsayed, Bassant Barakat, Emad Samaan
Source
Scientific reports
DOI
10.1038/s41598-025-24092-7
PubMed
41203719
Open original source
2012Observational human evidence
Evidence strength A · 88/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Efficacy and safety of desmopressin for treatment of nocturia: a systematic review and meta-analysis of double-blinded trials.

The purpose of this analysis was to evaluate the efficacy and safety of desmopressin for the treatment of nocturia.

Authors
Huantao Zong, Chenchen Yang, Xiaoxia Peng, Yong Zhang
Source
International urology and nephrology
DOI
10.1007/s11255-011-0054-3
PubMed
21898039
Open original source
2013Observational human evidence
Evidence strength A · 86/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Severe signs of hyponatremia secondary to desmopressin treatment for enuresis: a systematic review.

Dilutional hyponatremia is a serious adverse effect of desmopressin, a vasopressin analog that is widely prescribed to manage monosymptomatic enuresis.

Authors
Barbara Lucchini, Giacomo D Simonetti, Alessandro Ceschi, Sebastiano A G Lava, Pietro B Faré, Mario G Bianchetti
Source
Journal of pediatric urology
DOI
10.1016/j.jpurol.2013.02.012
PubMed
23619353
Open original source
2024Observational human evidence
Evidence strength A · 88/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Efficacy and safety of desmopressin in nocturia and nocturnal polyuria control of neurological patients: A systematic review and meta-analysis.

Evidence on the efficacy of desmopressin in nocturia in patients with neurological diseases is still very limited except for multiple sclerosis (MS).

Authors
Sakineh Hajebrahimi, Afra Darvishi, Reyhaneh HajEbrahimi, Nazli Asadi, Zahra Jafari Shendi, Negar Asiaban, Amirreza Naseri, Fatemeh Sadeghi-Ghyassi, Hadi Mostafaei, Hanieh Salehi-Pourmehr
Source
Neurourology and urodynamics
DOI
10.1002/nau.25291
PubMed
37746880
Open original source
2022Observational human evidence
Evidence strength A · 88/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

The efficacy and safety of desmopressin acetate applied for nocturia in benign prostatic hyperplasia patients: A systematic review and meta-analysis.

Desmopressin acetate was recommended for nocturia in benign prostatic hyperplasia (BPH) patients recently, but its effect and safety is still controversial.

Authors
Qihua Wang, Rami Alshayyah, Bo Yang
Source
Lower urinary tract symptoms
DOI
10.1111/luts.12423
PubMed
35034423
Open original source
2015Observational human evidence
Evidence strength A · 86/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Desmopressin to Prevent Rapid Sodium Correction in Severe Hyponatremia: A Systematic Review.

Hyponatremia is common among inpatients and is associated with severe adverse outcomes such as osmotic demyelination syndrome.

Authors
Thomas E MacMillan, Terence Tang, Rodrigo B Cavalcanti
Source
The American journal of medicine
DOI
10.1016/j.amjmed.2015.04.040
PubMed
26031887
Open original source
2018Observational human evidence
Evidence strength A · 88/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Desmopressin for treating nocturia in men.

To assess the effects of desmopressin as compared to other interventions in the treatment of nocturia in men.

Authors
Julia Han, Jae Hung Jung, Caitlin J Bakker, Mark H Ebell, Philipp Dahm
Source
BJU international
DOI
10.1111/bju.14183
PubMed
29489052
Open original source
Insufficient evidence

Desmopressin.

Source reference associated with Desmopressin. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source
other
PubMed
32119469
Open original source

Scientific context

Chemistry and represented biological context

Existing reviewed chemistry is preserved as scientific context. Chemistry and mechanism information do not establish clinical efficacy or safety.

Open chemistry and biological context ↓
Chemical identity

Molecular and structural record

Structured record
Molecular formula
C46H64N14O12S2
Molecular weight (Da)
1069.2
Amino acid sequence
1-deamino-8-D-arginine vasopressin: dCYFQNCP[d-Arg]G-NH2; Cys1-Cys6 disulfide
SMILES
C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N
InChI
InChI=1S/C46H64N14O12S2/c47-35(62)15-14-29-40(67)58-32(22-36(48)63)43(70)59-33(45(72)60-18-5-9-34(60)44(71)56-28(8-4-17-52-46(50)51)39(66)53-23-37(49)64)24-74-73-19-16-38(65)54-30(21-26-10-12-27(61)13-11-26)41(68)57-31(42(69)55-29)20-25-6-2-1-3-7-25/h1-3,6-7,10-13,28-34,61H,4-5,8-9,14-24H2,(H2,47,62)(H2,48,63)(H2,49,64)(H,53,66)(H,54,65)(H,55,69)(H,56,71)(H,57,68)(H,58,67)(H,59,70)(H4,50,51,52)/t28-,29+,30+,31+,32+,33+,34+/m1/s1
InChIKey
NFLWUMRGJYTJIN-PNIOQBSNSA-N

Chemical identity describes the recorded molecular information. It does not establish biological activity, clinical efficacy, safety, or therapeutic suitability.

Explore further

Continue through the research system

Move from this peptide record into the project's broader evidence, research, comparison, and methodology systems.

Research discovery

Compare peptides

Examine represented peptide records side by side.

Evidence system

Explore how scientific evidence is represented and reviewed.

Research hub

Enter the broader research and intelligence environment.

Methodology

Review project methods, boundaries, and interpretation rules.

Research

How the scientific record is developing

Chronology, unresolved research questions, opportunities, and researcher activity remain descriptive rather than evaluative.

Research chronology

  1. 1987 · study · Temporal status not established

    1-Desamino-8-D-arginine vasopressin (desmopressin) decreases operative blood loss in patients having Harrington rod spinal fusion surgery. A randomized, double-blinded, controlled trial.

    Annals of internal medicine

  2. 1995 · study · Temporal status not established

    Response to desmopressin as a function of urine osmolality in the treatment of monosymptomatic nocturnal enuresis: a double-blind prospective study.

    The Journal of urology

  3. 1999 · study · Temporal status not established

    Desmopressin resistant enuresis: pathogenetic and therapeutic considerations.

    The Journal of urology

  4. 1999 · study · Temporal status not established

    Desmopressin in the treatment of nocturnal polyuria in the male.

    BJU international

  5. 2001 · study · Temporal status not established

    Desmopressin usage in elective cardiac surgery.

    The Journal of cardiovascular surgery

  6. 2002 · study · Temporal status not established

    Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men.

    BJU international

  7. 2004 · study · Temporal status not established

    Evidence against a synergistic effect of desmopressin with conditioning in the treatment of nocturnal enuresis.

    The Journal of pediatrics

  8. 2010 · study · Temporal status not established

    Desmopressin improves platelet dysfunction measured by in vitro closure time in uremic patients.

    Nephron. Clinical practice

  9. 2011 · study · Temporal status not established

    Randomized comparison of long-term desmopressin and alarm treatment for bedwetting.

    Journal of pediatric urology

  10. 2012 · study · Temporal status not established

    Efficacy and safety of desmopressin for treatment of nocturia: a systematic review and meta-analysis of double-blinded trials.

    International urology and nephrology

  11. 2013 · study · Temporal status not established

    Severe signs of hyponatremia secondary to desmopressin treatment for enuresis: a systematic review.

    Journal of pediatric urology

  12. 2015 · study · Temporal status not established

    Desmopressin to Prevent Rapid Sodium Correction in Severe Hyponatremia: A Systematic Review.

    The American journal of medicine

  13. 2016 · study · Temporal status not established

    Desmopressin after cardiac surgery in bleeding patients. A multicenter randomized trial.

    Acta anaesthesiologica Scandinavica

  14. 2016 · study · Temporal status not established

    Side effects of desmopressin in patients with bleeding disorders.

    Haemophilia : the official journal of the World Federation of Hemophilia

  15. 2016 · study · Temporal status not established

    Desmopressin effectiveness in renal colic pain management: Systematic review and meta-analysis.

    The American journal of emergency medicine

  16. 2018 · study · Temporal status not established

    Claiming desmopressin therapeutic equivalence in children requires pediatric data: a population PKPD analysis.

    European journal of clinical pharmacology

  17. 2018 · study · Temporal status not established

    Desmopressin for treating nocturia in men.

    BJU international

  18. 2019 · study · Temporal status not established

    Efficacy and safety of desmopressin in women with nocturia: a systematic review and meta-analysis of randomized controlled trials.

    International urology and nephrology

  19. 2020 · study · Temporal status not established

    Efficacy and safety of 25 and 50 μg desmopressin orally disintegrating tablets in Japanese patients with nocturia due to nocturnal polyuria: Results from two phase 3 studies of a multicenter randomized double-blind placebo-controlled parallel-group development program.

    Lower urinary tract symptoms

  20. 2022 · study · Temporal status not established

    Moderate-intensity aerobic exercise vs desmopressin in adolescent males with mild hemophilia A: a randomized trial.

    Blood

  21. 2022 · study · Temporal status not established

    The efficacy and safety of desmopressin acetate applied for nocturia in benign prostatic hyperplasia patients: A systematic review and meta-analysis.

    Lower urinary tract symptoms

  22. 2023 · study · Temporal status not established

    Desmopressin for patients with spontaneous intracerebral haemorrhage taking antiplatelet drugs (DASH): a UK-based, phase 2, randomised, placebo-controlled, multicentre feasibility trial.

    The Lancet. Neurology

  23. 2024 · study · Temporal status not established

    Efficacy and safety of desmopressin in nocturia and nocturnal polyuria control of neurological patients: A systematic review and meta-analysis.

    Neurourology and urodynamics

  24. 2025 · study · Temporal status not established

    Desmopressin for nocturnal enuresis in children.

    The Cochrane database of systematic reviews

  25. 2025 · study · Temporal status not established

    Effect of desmopressin on bleeding outcomes after native renal biopsy: a systematic review and meta-analysis.

    Scientific reports

  26. 2026 · regulatory · Temporal status not established

    Regulatory review: approved

    United States (FDA — DDAVP)

  27. 2026 · regulatory · Temporal status not established

    Regulatory review: approved

    United States (FDA — DESMODA)

  28. Date unavailable · study · Temporal status not established

    Desmopressin.

    other

The represented chronology reflects records currently included in the governed dataset and does not claim to represent the entire scientific literature.

What still needs investigation

Claim traceability

No institutional claim record is currently represented for this peptide.

Evidence is missing or not represented as studied; this is not a conclusion that the intervention does not work.

Researchers represented in the evidence record12 bibliographic identities · open to inspect

These are bibliographic author identities derived from represented records. Name strings are not proof of unique real-world researcher identity, and publishing organizations are not treated as institutional affiliations.

P Abrams

2 represented evidence records

Years represented: 1999, 2002

Publishing organizations appearing in records: BJU international

A A McConnell

1 represented evidence record

Years represented: 1999

Publishing organizations appearing in records: BJU international

A B Belman

1 represented evidence record

Years represented: 1995

Publishing organizations appearing in records: The Journal of urology

A Cannon

1 represented evidence record

Years represented: 1999

Publishing organizations appearing in records: BJU international

A Franco

1 represented evidence record

Years represented: 2016

Publishing organizations appearing in records: Acta anaesthesiologica Scandinavica

A Mattiasson

1 represented evidence record

Years represented: 2002

Publishing organizations appearing in records: BJU international

A Stenberg

1 represented evidence record

Years represented: 1999

Publishing organizations appearing in records: The Journal of urology

Afra Darvishi

1 represented evidence record

Years represented: 2024

Publishing organizations appearing in records: Neurourology and urodynamics

Ahmed R A Moustafa

1 represented evidence record

Years represented: 2025

Publishing organizations appearing in records: Scientific reports

Alessandro Ceschi

1 represented evidence record

Years represented: 2013

Publishing organizations appearing in records: Journal of pediatric urology

Ali Falahati

1 represented evidence record

Years represented: 2020

Publishing organizations appearing in records: Lower urinary tract symptoms

Alison Maddocks

1 represented evidence record

Years represented: 2011

Publishing organizations appearing in records: Journal of pediatric urology

Connections

Follow the scientific relationships

Connections appear only when they are represented by the project’s underlying records.

Open 12 represented connections ↓

institution

BJU international

represented evidence source

institution

Lower urinary tract symptoms

represented evidence source

institution

The Journal of urology

represented evidence source

institution

Journal of pediatric urology

represented evidence source

institution

International urology and nephrology

represented evidence source

institution

The Lancet. Neurology

represented evidence source

institution

The Journal of pediatrics

represented evidence source

institution

The Journal of cardiovascular surgery

represented evidence source

institution

Annals of internal medicine

represented evidence source

institution

Nephron. Clinical practice

represented evidence source

institution

Blood

represented evidence source

institution

European journal of clinical pharmacology

represented evidence source

Traceability

Follow the record back to its source

The experience makes incomplete links visible instead of presenting a false impression of perfect provenance.

Source publication state

A governed source may be verified and approved for publication while its claim-to-evidence link is still incomplete.

Reviewer provenance state

“Human scientist reviewed: no” means that specific source-path attribution is not recorded. It does not silently negate the separate publication-review state.

Domain conclusion → Evidence

Connected

Evidence → Source

Connected

Source → Original record

Connected

Traceability documents how the project connects statements to records. It does not establish that a source is scientifically valid or that a claim is clinically true.

Reconciled for 6 domain conclusions and 0 featured studies.

Detailed study-to-domain mappings and original-source paths appear in the Desmopressin evidence-governance section.

Inspect the ranked source records

Observational archive

What contributors reported

Observational archive data is intentionally separated from published scientific evidence.

Observational boundary

Insufficient eligible observations are available for display under the current filters.

Insufficient eligible observations are currently represented to display aggregated findings for this peptide.

Regulatory context

Published jurisdictional records

Regulatory status is jurisdiction-specific and time-dependent. It is presented as context, not as a recommendation for use or a substitute for scientific evidence evaluation.

Research + media

Media connected to this scientific record

Only media explicitly linked through the project’s relationship system appears here.

No scientifically connected media is currently represented for this peptide.

Sources + provenance

Read the scientific record with its boundaries intact

The public record organizes reviewed evidence; it does not establish scientific truth by itself.
Association, mechanism, observation and regulatory status must not be represented as proof of clinical efficacy or safety.
Observational reports describe contributor experiences and cannot establish causation, effectiveness, safety or clinical benefit.
Contradictory and qualifying evidence must remain visible rather than being silently discarded.
Absence of represented evidence is not evidence that research does not exist.
Research gaps identify unresolved questions; they are not negative conclusions.
Regulatory status is distinct from scientific evidence quality.
Media relationships provide context and explanation; they do not increase the strength of scientific evidence.
A section with no represented records is an incomplete project record, not a scientific conclusion.
Researcher and institutional relationships are shown only when supported by represented records and must not be interpreted as rankings or endorsements.

Generated: 11/8/2026, 5:24:49 PM

global evidence atlas

Desmopressin research, ranked and separated by purpose

This is a deduplicated literature screening registry—not a claim that every mention directly proves efficacy or safety. Machine proposals remain visibly separate from governed human appraisal.

713Discoverable source universe
500Ranked screening records
6Research domains
0Accountably approved conclusions

500 matching records · ranked 2026-09-18

Page 1 of 20

Count reconciliation: 713 discoverable source records match the peptide identity query; 500 are retained in this bounded, ranked screening view; 0 belong to the separate governed layer labeled “Accountably approved conclusions.” Domain totals overlap because one publication may inform several questions.

governance and regulatory context

Desmopressin: what this atlas does and does not establish

Last checked
2026-09-18
Accountable publication approval
Not yet approved by a named accountable reviewer. Machine screening only.

No new outcome conclusion is inferred from discovery metadata. Named accountable approval is required for governed scientific conclusions.

Regulatory status by jurisdiction

Absence of a record in this pass is not proof that no authorization exists. Status must remain jurisdiction-, product-, formulation-, and date-specific.

  • United States (FDA — DDAVP)approvedchecked 2026-09-09

    DDAVP desmopressin acetate tablets are FDA-approved as antidiuretic replacement therapy in central diabetes insipidus and for management of temporary polyuria and polydipsia following head trauma or pituitary-region surgery, subject to current labeling.

    FDA Drugs@FDA — DDAVP NDA 019955
  • United States (FDA — DESMODA)approvedchecked 2026-09-09

    DESMODA desmopressin acetate oral solution is FDA-approved for antidiuretic replacement therapy in patients with central diabetes insipidus (arginine vasopressin deficiency), according to its current product labeling.

    FDA Drugs@FDA — DESMODA NDA 219873

5 FDA structured product label record(s) were identified for this compound name in openFDA. Label presence reflects an approved product exists under that name; it is not a claim about the specific formulation, dose, or use being discussed anywhere else on this page.

No machine-proposed evidence-strength grades exist yet for this compound; all screening records are unassigned pending further review.

Desmopressin evidence · ranking key

How evidence is ranked

A tier describes the evidentiary role and design strength of a source. It is not a popularity score, proof that every conclusion is correct, or a substitute for claim-level review.

A

Practice-defining evidence

Large, well-conducted randomized trials; prespecified major outcomes; rigorous systematic reviews or meta-analyses; and major regulatory assessments.

B

Strong supporting evidence

Smaller randomized trials, strong prospective cohorts, prespecified secondary analyses, and high-quality comparative-effectiveness studies.

C

Contextual evidence

Retrospective cohorts, claims-database studies, pharmacovigilance analyses, mechanistic human research, and well-documented case series.

D

Signal-generating evidence

Case reports, conference abstracts, preclinical research, hypothesis-generating analyses, and expert commentary.

Tier and confidence answer different questions

Tier classifies source design and evidentiary role. Confidence reflects risk of bias, sample size, comparator quality, outcome relevance, follow-up, missing data, directness, replication, reporting quality, and whether conclusions stay within the measured results.

Funding and conflicts are disclosed and considered, but sponsorship never automatically changes a tier. Corrections, retractions, and expressions of concern override the original rating.

peptide explorer

Structural visualization and provenance

Evidence-class labeling remains visible even when interactive rendering is unavailable. Representative geometry is not an experimentally determined or predicted biological conformation.

Fully specified molecular identity

Molecular formula
C46H64N14O12S2
Molecular weight
1069.2 g/mol
Exact identity / sequence notation
1-deamino-8-D-arginine vasopressin: dCys-Tyr-Phe-Gln-Asn-Cys-Pro-D-Arg-Gly-NH2; Cys1–Cys6 disulfide
Identity-defining modifications
  • 1-deamino
  • D-Arg8
  • Cys1–Cys6 disulfide
  • C-terminal glycinamide
PubChem CID
5311065
InChIKey
NFLWUMRGJYTJIN-PNIOQBSNSA-N

Cyclization and D-stereochemistry are exact in notation; the viewer remains representative.

Sources: NIH PubChem — Desmopressin · reviewed 2026-09-17

Representative sequence-derived model
Structure source
Generated from this record's governed amino-acid sequence
Identifier
Not applicable — not a database structure
Method
Schematic layout ordered by residue position only; not a molecular-dynamics, homology, or fold prediction
Confidence / limitations
Illustrative only. Not physically accurate; carries no structural, binding-site, or activity meaning.
Provenance
WPF governed PeptideChemistry record
Retrieved / last reviewed
2026-09-17

This is a representative, sequence-derived model ordered by residue position only. It is not the peptide's experimentally determined or predicted biological conformation, and it carries no claim about real bond angles, distances, secondary structure, binding sites, or activity.

Suggested citation

  • APA

    World Peptide Foundation. (n.d.). Desmopressin — Peptide Scientific Intelligence. World Peptide Foundation. (Updated September 20, 2026.) https://www.worldpeptidefoundation.org/directory/desmopressin

  • AMA / Vancouver

    World Peptide Foundation. Desmopressin — Peptide Scientific Intelligence. World Peptide Foundation website. Updated September 20, 2026. https://www.worldpeptidefoundation.org/directory/desmopressin